BioCryst Pharmaceuticals (BCRX) to Release Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is expected to post its quarterly earnings results before the market opens on Monday, February 24th. Analysts expect BioCryst Pharmaceuticals to post earnings of ($0.07) per share and revenue of $130.05 million for the quarter. Individual interested in registering for the company’s earnings conference call can do so using this link.

BioCryst Pharmaceuticals Trading Down 1.9 %

BioCryst Pharmaceuticals stock opened at $9.21 on Friday. The firm has a 50 day moving average of $8.01 and a 200 day moving average of $7.84. The firm has a market capitalization of $1.91 billion, a price-to-earnings ratio of -15.10 and a beta of 1.75. BioCryst Pharmaceuticals has a 12-month low of $4.03 and a 12-month high of $9.50.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on the stock. Needham & Company LLC increased their target price on shares of BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the stock a “buy” rating in a report on Monday, January 13th. Royal Bank of Canada restated an “outperform” rating and issued a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Tuesday, November 5th. JMP Securities restated a “market outperform” rating and issued a $18.00 price target on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Evercore ISI upped their price target on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the stock an “outperform” rating in a research note on Monday, January 13th. Finally, Barclays upped their price target on BioCryst Pharmaceuticals from $7.00 to $8.00 and gave the stock an “equal weight” rating in a research note on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, BioCryst Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $15.50.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.